GJA4 gene inhibition may represent a potential target for novel antithrombotic therapies

Back

ESC Professional Premium Access

GJA4 gene inhibition may represent a potential target for novel antithrombotic therapies

Session: Biomarkers to assess cardiovascular risk

Topic: Cardiovascular Risk Assessment

Speaker: Doctor D. Sa (Funchal, PT)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Debora Sa

Hospital Dr. Nelio Mendonca, Funchal (Portugal)

0 follower

6 more presentations in this session

Expression of myostatin and folistatin as a response to high-load strength training to counteract the loss of muscle mass in heart failure with preserved ejection fraction

Speaker: Doctor J. Lara Vargas (Mexico City, MX)

Assessment of experimental circulating biomarkers in volume and pressure overload: insights from a cohort study

Speaker: Mrs D. Csengeri (Hamburg, DE) Professor R. Schnabel (Hamburg, DE)

Circulating metabolites associate with the QT interval in individuals without prevalent cardiovascular disease.

Speaker: Doctor W. Young (London, GB)

OSTEO18, a novel urinary proteomic signature, associated with osteoporosis in heart transplant recipients

Speaker: Doctor Y. Yu (Leuven, BE)

AI-CAC significantly improves on Coronary Artery Calcium (CAC) score for predicting all cardiovascular events: the Multi-Ethnic Study of Atherosclerosis

Access

Slides

Video

Access the full session

Biomarkers to assess cardiovascular risk

Speakers: Doctor D. Sa, Doctor J. Lara Vargas, Mrs D. Csengeri, Professor R. Schnabel, Doctor W. Young...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources